Navigation Links
Lightlake Therapeutics Commences Two-Week Patient Trial for Treatment of Opioid Overdose with National Institute on Drug Abuse (NIDA)
Date:9/24/2013

LONDON, Sept. 24, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc. ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that the Company has begun a two-week clinical trial designed to evaluate the pharmacokinetic properties of Lightlake's intranasal naloxone application in 14 healthy volunteer subjects.

The trial, which began on September 23rd, 2013, is being conducted in partnership with the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health ("NIH").

Naloxone is a medicine currently available through injection that can rapidly reverse the overdose of prescription and illicit opioids. Lightlake is working on a new intranasal delivery system for the delivery of naloxone that could widely expand its availability and use in preventing opioid overdose deaths, a public health problem of epidemic proportion in the U.S. According to the Centers for Disease Control and Prevention, 16,651 people died from prescription opioid overdose in the U.S. in 2010, a significant increase from the 4,030 overdose deaths in 1999.

Assuming favorable outcomes from this study, NIDA plans to file an IND for a larger study. The expected goal of Lightlake's partnership with NIDA is to have an FDA approved intranasal naloxone solution for the reversal of opioid overdoses that can be brought to market within 12 to 18 months.

"We are very pleased to begin our trial with NIDA as we believe this is a key step that will help us to formally deliver an intranasal naloxone spray aimed at reversing opioid overdoses to the healthcare community," stated Dr. Roger Crystal, CEO of Lightlake. "Naloxone is the ideal opioid antagonist and we are confident that the data from this trial can also be used to supply critical data for other Lightlake studies that involve va
'/>"/>

SOURCE Lightlake Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
2. Moderna Therapeutics Named a "Fierce 15" Biotech Company for 2013
3. Protagonist Therapeutics Expands Series B Financing to $18 Million with Addition of $4 Million from Pharmstandard
4. PTC Therapeutics to Present at European Pediatric Neurology Society Congress
5. Technical Study: Gilead Sciences Inc., Halozyme Therapeutics Inc., NPS Pharmaceuticals Inc., and InterMune Inc.
6. Adheron Therapeutics Names New Senior Leadership
7. Case Report Suggests Microbiome Therapeutics NM504 May Improve Tolerability of Metformin While Improving Blood Glucose Control
8. Echo Therapeutics Sends Response to Shareholder Letter
9. Convoy Therapeutics to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
10. Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
11. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 BCC Research ( ... DIGITAL POLYMERASE CHAIN REACTION (PCR) TECHNOLOGY: GLOBAL MARKETS , ... technology reached nearly $140 billion in 2013. This is ... a five-year compound annual growth rate (CAGR) of 28.6%. ... of interesting and exciting possibilities within the broader PCR ...
(Date:7/10/2014)... Burkina Faso (PRWEB) July 10, 2014 ... Faso, today have access to an additional family ... increase access to contraception at all levels of ... a lower-dose formulation of a widely used contraceptive—Pfizer’s ... system. , Burkina Faso is the first of ...
(Date:7/10/2014)... July 10, 2014 Unraveling life’s mysteries ... The Archer Family purchased a DNA test ... but ended up with a lifetime of memories, sharing, ... the family members’ DNA genuinely brought the family closer ... search deeper into genetic history and prior to taking ...
(Date:7/10/2014)... July 10, 2014  Franciscan St. Anthony ... capnography for respiratory monitoring outside the operating ... leaders in embracing state-of-the-art patient safety technology. ... are breathing and can alert medical caregivers ... the amount of carbon dioxide the patient ...
Breaking Biology Technology:Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 2Global Market for Digital Polymerase Chain Reaction Technology to Reach $490 Billion by 2018; Equipment Sector Accounts for the Fastest Growing Segment With 33% CAGR 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... database to explore, understand, manage, and share next-generation ... Inc., the leader in sequence data management, today ... Expression Workflow designed to enable researchers working with ... is the second such workflow to be delivered ...
... May 5 Sequella, Inc., a clinical-stage biopharmaceutical company ... start of its Phase 1B trial for SQ109 with ... a new diamine antibiotic intended to replace one or ... patient therapy, was granted U.S. FDA Fast Track designation ...
... influenza virus-like particle (VLP) vaccine progresses with study designed ... May 5 Novavax, Inc. (Nasdaq: NVAX ... second clinical trial of its virus-like particle (VLP) seasonal ... this Phase II randomized, placebo controlled clinical trial has ...
Cached Biology Technology:GenomeQuest, Inc. Announces Digital Gene Expression Solution Within Its Sequence Data Management Platform 2Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109 2Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 2Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 3Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 4
(Date:7/11/2014)... 2014 Research and Markets has ... Market - Industry Analysis Size Share Growth Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 The ... a need for high level security in both private ... such as username and passwords, tokens etc. are vulnerable ...
(Date:7/10/2014)... 2014  The American Academy of Forensic Sciences ... and Technology (NIST) and the Department of Justice ... forensic science expert members to the Forensic Science ... of the NIST,s Organization of Scientific Area Committees ... appointments made to the new FSSB that has ...
(Date:7/10/2014)... BLUE BELL, Pa. , July 2, 2014  Unisys ... The Netherlands , Unisys Nederland N.V., today announced that ... (DJI) to deliver, implement and manage a new Basic Provision ... . Unisys won the contract with a ... for identity management software. The term of the contract is ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3
... its wood and cottony fibers, the kapok tree now ... for decades: the notion that African and South American ... million years ago. , Research by University of Michigan ... perhaps other rainforest--trees colonized Africa after the continents split ...
... modification to successfully manipulate the growth in height of trees, ... similar to normal trees – but after several years of ... few inches. , This is a “proof of concept” that ... It opens the door to a wide variety of new ...
... that will be published online in advance of its July ... colleagues (The Salk Institute and HHMI) demonstrate that endosomes can ... animals. , "These findings will influence our thinking of the ... why cells use them as signaling compartments," noted lead author ...
Cached Biology News:The kapok connection -- Study explains rainforest similarities 2Researchers demonstrate way to control tree height 2Researchers demonstrate way to control tree height 3
... tissue extracts (liver, kidney, spleen, and heart) and ... It was also tested with microsomal fractions prepared ... simple and reliable method for measuring NDPase activity ... the inorganic phosphate released from NDP by the ...
... CAST Equine EIA Principle: ... LTD4 and LTE4 are products ... 5-lipoxygenase and glutathione-S-transferase. In the ... "Slow Reacting Substances of Anaphylaxis ...
... stress is the condition in which a ... stimuli and the various antioxidants. Oxidative ... pathogenesis of several diseases, including artherosclerosis, chronic ... possesses several antioxidant systems that are very ...
... Compound(s) tested through ... enzyme assays spanning a ... assay panel includes many ... and several non-selective assays. ...
Biology Products: